Live tape
Top 8, mentions 7d7,050SPCX1,388 mentions▲ +0.09GOOGL1,284 mentions▲ +0.05NVDA1,140 mentions▲ +0.09MSFT799 mentions▲ +0.04QQQ672 mentions▲ +0.08META614 mentions▲ +0.04SPY586 mentions▲ +0.06AMZN567 mentions▲ +0.07

Equity · Healthcare

LGND

NASDAQ

Ligand Pharmaceuticals Incorporated

$289 +0.35% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
Price · Chart
29 sessions
$310 $270 13 Jul 10 Sep

The line runs $309 on 13 July through $289 on 10 September, on a scale from $270 to $310. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 29 sessions, 13 Jul – 10 Sep 2026
Market cap $5.8B
P/E (TTM) 30.0
52-week range $165 – $323
Avg volume 28.0K

as of Sep 10, 2026

LGND insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Oct 2026
Open-market buys 0
Open-market sells 1
Net sold $1.52M
Non-trade filings 1
Date Insider Type Shares Value
02 Oct 2026 Reardon Andrew CLO & Secretary Sell 5,000 $1.52M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Oct 2026 Reardon Andrew CLO & Secretary Option exercise 340 $18K

LGND reported financials

SEC EDGAR XBRL SEC EDGAR

LGND reported revenue of $268.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was $124.5M.

Figure Reported Period
Revenue $268.1M 31 Dec 2025 fiscal year
Net income $124.5M 31 Dec 2025 fiscal year
Diluted EPS $6.13 31 Dec 2025 fiscal year
Total assets $2.2B 30 Jun 2026 at period end
Total equity $967.5M 30 Jun 2026 at period end

LGND earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.22 —
31 Mar 2026 Q1 2026 −$0.67 —
31 Dec 2025 FY 2025 $6.13 —
30 Sep 2025 Q3 2025 $5.68 —
30 Jun 2025 Q2 2025 $0.24 —
31 Mar 2025 Q1 2025 −$2.21 —
31 Dec 2024 FY 2024 −$0.22 —
30 Sep 2024 Q3 2024 −$0.39 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

LGND institutional holders

SEC Form 13F SEC EDGAR

5 of the 45 institutional funds we track reported a LGND position for the quarter ended 30 Jun 2026 — a combined $66.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Fisher Asset Management Held (±25%) −5.1% shares 121,440 $38.4M
D. E. Shaw & Co. Trimmed −27.9% shares 56,515 $17.9M
Two Sigma Investments New position 18,825 $6.0M
AQR Capital Management Added +40.4% shares 10,444 $3.3M
Millennium Management New position 3,975 $1.3M
Citadel Advisors Exited
Man Group Exited
Marshall Wace Exited

LGND fails-to-deliver

SEC CNS data SEC

On 11 Sep 2026, 2,018 shares of LGND failed to deliver (about $584K).

Settlement date Shares failed Notional % of shares out
11 Sep 2026 2,018 $584K 0.010%
03 Sep 2026 5,586 $1.6M 0.028%
02 Sep 2026 211 $60K 0.001%
01 Sep 2026 10 $3K <0.001%
31 Aug 2026 1,681 $472K 0.008%
28 Aug 2026 182 $52K 0.001%

Congressional trades in LGND

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in LGND is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 Jan 2026.

Date Member Type Amount
15 Jan 2026 filed 13 Feb 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings